window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 17, 2026

  • News
  • About Us
Contact Us

Series B financing

  • Clinical Development,Neurosciences,Partnerships & Funding,Pharmaceuticals and therapeutics,Rare Diseases,Research & Development

    NRG Therapeutics closes oversubscribed £50m series B to advance clinical data in Parkinson’s and proof of concept in ALS/MND

    NRG Therapeutics Ltd, a neuroscience company developing treatments targeting mitochondrial [...]

    September 8, 2025
  • Clinical Development,Market Access & Commercialization,Oncology,Partnerships & Funding

    VIVES Partners joins Nuclidium AG’s €84M Series B Financing to advance copper-based radiopharmaceuticals

    VIVES Partners, managing company of VIVES Funds, has joined a [...]

    July 10, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Veristat names Kim McLean Boericke as CEO to drive next phase of clinical research growtheristat names Kim McLean Boericke as CEO to drive next phase of clinical research growth
    Categories: Biotech, Clinical Development, Clinical studies, Clinical Trials, Healthcare leadership, Movers & Shakers, Rare Diseases
  • Will Edwards appointed CEO as Astoriom expands international storage and biorepository operations
    Categories: Biomanufacturing, CDMOs & Manufacturing, Healthcare leadership, Movers & Shakers, Pharmaceuticals and therapeutics
  • CombinAbleAI to be acquired by insitro to expand AI drug discovery platform
    Categories: Artificial Intelligence, Biotech, Drug Development, Mergers & Acquisitions, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top